Yangguang Anjin Completes Over CNY 100 Million Pre-A Round Financing to Accelerate R&D of Nav1.8 Small Molecule Innovative Drugs

Recently, Yangguang Anjin (Nanjing) Biopharmaceutical Co., Ltd. (hereinafter referred to as “Yangguang Anjin”) announced the completion of an over CNY 100 million Pre-A round financing. This round was led by Qiming Venture Partners, with participation from BioTrack Capital and Tsing-Yuan Capital.

The proceeds from this financing will be primarily used for the preclinical and early clinical stage development of Yangguang Anjin’s pain treatment R&D pipeline, further accelerating the R&D of small molecule innovative drugs targeting the sodium ion channel Nav1.8, and supporting the company’s continuous advancement of drug development for pain-related ion channel targets such as Nav1.8 and Nav1.7.

1. Yangguang Anjin Focuses on R&D of Innovative Drugs for Pain Treatment

Founded in 2021, Yangguang Anjin is a biopharmaceutical company specializing in the research and development of innovative drugs.

The company was co-founded by Professor Lei Xiaoguang of Peking University and Dr. Yang Yong, a clinician at the Institute of Dermatology, Chinese Academy of Medical Sciences. The R&D team has a long-term focus on basic research related to ion channels and the development of innovative drugs.

According to public information, Yangguang Anjin’s current key disease areas of focus include:

• Alopecia;
• Peripheral pain;
• Pruritus (itching);
• Other disease areas with significant unmet clinical needs.

The company primarily focuses on the R&D of new small molecule innovative drugs, with a key emphasis on the Nav1.8 and Nav1.7 sodium ion channels, which are closely related to pain perception.

By conducting R&D around novel drug targets, Yangguang Anjin aims to establish an innovative drug R&D pipeline covering the field of pain treatment.

2. Over CNY 100M Pre-A Financing to Support Further Development of Pain Treatment Pipeline

This round of financing is crucial capital support for Yangguang Anjin during its innovative drug R&D phase.

The company stated that the funds raised will be mainly used for the preclinical and early clinical stage development of its global pain treatment R&D pipeline.

For innovative drug companies, moving from preclinical research to the clinical development stage typically requires continuous R&D investment and the completion of a series of tasks including chemistry, manufacturing, and controls (CMC), pharmacology and toxicology, preclinical studies, and regulatory filings.

Therefore, this financing will primarily support Yangguang Anjin in advancing its core R&D pipeline and accelerating the progression of relevant candidate drugs into the clinical stage.

The company previously expected to initiate IND filing-related work in 2025, moving its core Nav1.8 inhibitor into the clinical development phase.

3. Nav1.8 Becomes an Important Target for R&D of New Non-Opioid Analgesics

There has always been a significant clinical need for pain treatment.

According to Yangguang Anjin and related public data, there is a large number of chronic pain patients globally, and China also has a huge demand for pain treatment. At the same time, although traditional opioid analgesics have strong pain-relieving effects, their addictive potential and related safety issues limit their long-term and widespread use.

Therefore, developing non-opioid analgesics targeting new biological mechanisms of pain has become one of the important directions for innovative drug R&D.

Sodium ion channels are a crucial part of the pain signaling pathway, with Nav1.8 and Nav1.7 being closely related to pain perception and nerve signal transmission.

Developing selective small molecule inhibitors targeting these ion channels provides a new direction for the R&D of novel analgesics.

4. Nav1.8 Inhibitors Attract Global Attention in Innovative Drug R&D

In recent years, the Nav1.8 target has garnered attention from the global innovative drug R&D field.

Public information shows that Vertex’s Nav1.8 inhibitor, VX-548, has announced Phase III clinical study data for moderate to severe acute pain, bringing the Nav1.8 target into the focus of global innovative analgesic drug R&D.

This R&D progress has further validated the industry’s interest in Nav1.8 as a target for non-opioid analgesics.

Against this backdrop, domestic companies conducting innovative drug R&D around Nav1.8 have also attracted the attention of the capital market and industrial investment institutions.

Yangguang Anjin’s ongoing Nav1.8 small molecule innovative drug pipeline is a vital part of the company’s pain treatment R&D strategy.

5. Yangguang Anjin Continues to Build its Pipeline of Ion Channel Drugs for Pain

In addition to Nav1.8, Yangguang Anjin also focuses on other ion channel targets related to pain perception, such as Nav1.7.

The company plans to continuously expand its R&D pipeline in the field of pain treatment, primarily through independent R&D, while also combining it with co-development models.

This R&D strategy aims to establish a more complete R&D system for innovative pain treatment drugs by continuously building a pipeline around promising ion channel targets.

For innovative drug companies, the R&D risk of a single candidate drug is high. By establishing an R&D platform around core technologies and targets and gradually forming a multi-product pipeline, companies can create more possibilities for subsequent clinical development and long-term growth.

6. Capital Supports the Transition of Innovative Drugs from Preclinical to Clinical Development

This financing round occurs as Yangguang Anjin’s core R&D pipeline is advancing further.

From the perspective of the innovative drug R&D cycle, preclinical research is a crucial stage before a drug enters human clinical trials. After completing candidate drug screening and preclinical research, companies need to proceed with IND filings, clinical trials, and subsequent registration and development.

Therefore, for biopharmaceutical companies in the R&D stage, financing is not only a way to supplement R&D funds but also a vital means to support the core pipeline in crossing key R&D milestones.

Yangguang Anjin’s completion of the over CNY 100 million Pre-A round financing will provide financial support for the subsequent development of its pain treatment R&D pipeline.

7. Capital and Innovative Drug R&D Form a Long-Term Synergy

The biopharmaceutical industry is characterized by long R&D cycles, large capital investment, and high technical risks.

Especially for innovative drug companies, from early R&D to clinical development and commercialization, they require continuous support from capital, R&D resources, clinical resources, and industrial partners.

Therefore, early-stage financing in the healthcare sector needs to not only focus on the company’s current R&D progress but also comprehensively evaluate:

• The value of core technologies and targets;
• Product pipeline layout;
• Clinical development potential;
• The R&D capabilities of the team;
• Intellectual property and technical barriers;
• Unmet clinical needs;
• Subsequent financing needs;
• Commercialization and industrial cooperation potential.

Yangguang Anjin’s investment of this financing round’s proceeds into its core R&D pipeline also reflects the demand of innovative drug companies for long-term capital support at critical R&D stages.

8. Future Plans to Continue Advancing Innovative Drug R&D for Pain Treatment

Yangguang Anjin has stated that it will continue to focus on promising ion channel targets in the pain field, prioritizing independent R&D while also considering co-development to further enhance its pain treatment R&D pipeline.

The company plans to accelerate the clinical development process of its products both domestically and internationally through flexible clinical development strategies and continue to explore global market development opportunities.

For Yangguang Anjin, after the completion of this Pre-A financing, its core task will be to further focus on advancing its R&D pipeline and subsequent clinical development.

As pain-related targets like Nav1.8 continue to attract attention from the global innovative drug industry, the progress of Yangguang Anjin’s subsequent clinical development will be a key point of observation for its future R&D and capital market development.

Yangguang Anjin Financing Event Information

About T-Capital

T-CAPITAL is a boutique investment bank focused on the broad healthcare sector, providing capital transaction services such as equity financing, M&A and restructuring, divestitures, licensing and joint ventures, and cross-border transactions to healthcare companies.

T-Capital focuses on healthcare fields such as new drug R&D, medical devices, medical diagnostics, high-value consumables, healthcare services, and emerging technologies. It is committed to connecting enterprises with capital and domestic markets with international resources, providing capital and industrial resource support for the development of healthcare enterprises.